Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

• Status: Active, not recruiting
• Trial end date: 2025-07-03
• Target enrollment: 0
• Participant gender: All

Summary

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Subject was treated in Study 20090

• Age less than 13 months of chronological age

• Signed informed consent from parent(s)/legally authorized representative(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

• Subject has a condition preventing participation in the study, or performance of study procedures.